Skip to main content
PatentCliff

Updated April 2026 · USPTO PatentsView

CPC C12

Biochemistry & Genetic Engineering Patent Landscape

70 patents tracked across 2 companies in CPC C12.

The Biochemistry & Genetic Engineering technology class (CPC C12) covers 70 U.S. patents tracked here, held across 2 companies. Filing activity, top patent holders, and recent grants below all come directly from USPTO records.

Patent landscape for Biochemistry & Genetic Engineering technology (CPC class C12). Covers innovations in biochemistry & genetic engineering from leading companies worldwide.

Biochemistry & Genetic Engineering at a Glance

70 patents tracked under Biochemistry & Genetic Engineering. Smaller technology classes can be either nascent areas with growing filing activity or legacy areas where filing has slowed — the yearly trend on this page is the easiest way to tell which.

Pfizer (38 patents, grade D) and Merck (32, grade D) hold the top two positions in Biochemistry & Genetic Engineering. The grade column reflects each company's overall Patent Strength Score across its full portfolio, not just patents in this technology class.

Patent Activity by Year

2012
2
2013
1
2014
2
2015
1
2016
2
2018
2
2019
3
2020
4
2021
3
2022
4
2023
4
2024
5
2025
2
2026
6
2027
2
2028
1

Filing activity in Biochemistry & Genetic Engineering has accelerated, with the most recent five years averaging about 3 new patents per year — roughly 19% above the earlier window. Acceleration often correlates with a technology shift attracting fresh corporate R&D, and it tends to push expiration cliffs further out as new filings replace older ones.

Recent Patents in Biochemistry & Genetic Engineering

Patent #TitleAssigneeGrantedExpiresClaimsStatus
10002748Method for integrated cloud genetic modificationMerckJan 16, 2028Apr 21, 20443918.0y left
10002751Novel configurable digital compound and synthesis thereofMerckAug 2, 2027Aug 17, 20442418.4y left
10002701Method of treating disease using distributed 5G therapyPfizerJul 8, 2027Dec 2, 20442718.7y left
10002714Method for scalable diagnosis using digitalPfizerDec 19, 2026Sep 24, 20432317.5y left
10002715Method for high-performance blockchain genetic modificationPfizerSep 18, 2026Sep 7, 20441418.4y left
10002699Medical device for adaptive 5G deliveryPfizerSep 17, 2026Jan 17, 20431516.8y left
10002690Method for preparing enhanced edge derivativesPfizerSep 11, 2026Aug 1, 20433417.3y left
10002679Recombinant neural protein with autonomous activityPfizerAug 10, 2026Aug 9, 20434017.3y left
10002724Method for integrated CMOS genetic modificationMerckJan 15, 2026Aug 2, 20421016.3y left
10002695Pharmaceutical composition comprising advanced analog compoundsPfizerOct 7, 2025Jul 17, 20423616.3y left
10002689Novel high-performance CMOS compound and synthesis thereofPfizerAug 1, 2025Jul 24, 20422916.3y left
10002749Therapeutic agent with configurable MEMS mechanismMerckOct 19, 2024Feb 25, 20424015.9y left
10002678Novel optimized AI-driven compound and synthesis thereofPfizerSep 16, 2024Aug 21, 20403514.4y left
10002753Medical device for improved lidar deliveryMerckJul 24, 2024Feb 19, 20413414.9y left
10002674Recombinant graphene protein with configurable activityPfizerMay 17, 2024Feb 24, 20424215.9y left
10002757Method for optimized diagnosis using analogMerckFeb 17, 2024Dec 20, 2041815.7y left
10002740high-performance chemical composition with photonic propertiesMerckDec 15, 2023Dec 13, 2041615.7y left
10002762Method of treating disease using adaptive lidar therapyMerckNov 14, 2023Dec 20, 20403814.7y left
10002687advanced 5G enzymatic processPfizerAug 6, 2023Apr 13, 20412815.0y left
10002673Method of treating disease using distributed blockchain therapyPfizerJan 18, 2023Feb 17, 20394612.9y left

What Expirations Mean for Biochemistry & Genetic Engineering

As patents in Biochemistry & Genetic Engineering expire, the underlying methods and apparatuses enter the public domain. Competitors gain freedom to operate without licensing the original claims, and downstream products incorporating the formerly protected technology can ship without a royalty stack. This is the ground-truth mechanism that drives generic-drug economics and the broader competitive dynamics in semiconductor process generations and consumer electronics platforms.

For pharmaceutical and biotech CPC classes, drug-specific exclusivities tracked in the FDA Orange Book can delay generic entry past patent expiration. For non-drug technology classes, expiration is a cleaner trigger — competitors generally gain freedom-to-operate immediately. Either way, the underlying expiration math comes from USPTO records.

How This Patent Landscape Is Built

Patents are assigned to Biochemistry & Genetic Engineering based on their primary CPC classification (C12) as recorded by USPTO examiners. Total counts include all patents in the tracked dataset that carry this CPC prefix; recent-patent and yearly-trend tables are derived from the same record set. Each company\'s grade reflects its overall Patent Strength Score across its entire tracked portfolio, not just patents in this CPC class. Read the full methodology for the data pipeline, score weights, and known limitations.

Frequently Asked Questions

What is the Biochemistry & Genetic Engineering CPC class?

Biochemistry & Genetic Engineering corresponds to Cooperative Patent Classification (CPC) prefix C12, the international system used by the USPTO and EPO to organize patents by technical subject matter. Patent landscape for Biochemistry & Genetic Engineering technology (CPC class C12). Covers innovations in biochemistry & genetic engineering from leading companies worldwide. CPC classes are assigned by patent examiners and update as the technology evolves, so the patent set tracked here reflects the current classification of every included patent.

Who are the top patent holders in Biochemistry & Genetic Engineering?

Pfizer (38 patents), Merck (32 patents) are the leading holders in Biochemistry & Genetic Engineering. Patent counts at the company level are useful for spotting concentration, but they do not tell you about claim strength — for a finer signal, see each company's Patent Strength Score grade in the table below.

How many Biochemistry & Genetic Engineering patents will expire soon?

Per-year expiration counts for this technology class can be derived from the recent patents table on this page combined with each patent's expiration date — patents typically expire 20 years from earliest non-provisional filing. For year-by-year expiration totals across all CPC classes, see the expiring-year pages on this site, which break down each year's cohort by company and technology.

What happens when patents in Biochemistry & Genetic Engineering expire?

When a patent expires, its claims enter the public domain. For Biochemistry & Genetic Engineering, that means competitors can implement the underlying methods or apparatus without licensing fees. The practical impact varies — in regulated areas like pharmaceuticals, FDA-granted exclusivities can extend market protection past patent expiry. In unregulated technology areas, expiration usually translates directly into freedom-to-operate for new entrants.

Where does Biochemistry & Genetic Engineering patent data come from?

All patent data is sourced from the U.S. Patent and Trademark Office through the PatentsView and Open Data Portal APIs. CPC classifications are assigned by USPTO examiners and are part of the official patent record. Verify any individual patent through USPTO Patent Public Search (ppubs.uspto.gov) or Google Patents.

All companies →Plain-English guides →Methodology →

Sources: U.S. Patent and Trademark Office (PatentsView, Open Data Portal). Public-domain federal data. Cite as: "PatentCliff, Biochemistry & Genetic Engineering landscape, April 2026. Data: USPTO."

Last updated 2026-04-10 · 70 patents tracked in Biochemistry & Genetic Engineering.